FHD-609

Target: This ligand targets bromodomain-containing protein 9 (BRD9) in biochemical or cellular target-engagement studies.

Mechanism of Action: Used as the target-protein recognition element, this ligand provides the binding interface for bromodomain-containing protein 9 (BRD9). In PROTAC design, a derivatizable position on the ligand can be connected through an optimized linker to an E3 ligase ligand, such as a CRBN, VHL, or IAP recruiter, while preserving productive target engagement. The resulting bifunctional molecule brings bromodomain-containing protein 9 (BRD9) into proximity with the recruited E3 ligase, enabling ternary-complex formation. If the complex has favorable geometry and residence time, target lysine ubiquitination is promoted, leading to proteasome-dependent degradation in experimental systems.

• PROTAC-Mediated Degradation: FHD-609 can be used as a ligand component in PROTAC constructs to recruit an E3 ligase and drive ubiquitination of the target protein. By tuning linker length and attachment chemistry, researchers can optimize ternary-complex formation, enhance ubiquitin transfer, and achieve selective, concentration-dependent degradation rather than mere inhibition.

• Ternary Complex Optimization: FHD-609-based PROTACs support systematic evaluation of cooperative binding between the target ligand, E3 ligase recruiter, and the target protein. Researchers can map how structural variations in FHD-609 influence binding kinetics, stabilize the ternary complex, and improve degradation potency across cell-based and biochemical degradation assays.

• Pathway Mechanism Studies: Using FHD-609 in targeted protein degradation workflows enables mechanistic dissection of how specific proteins control signaling and cellular phenotypes. Degradation readouts such as time-resolved protein loss, rescue experiments, and ubiquitination profiling can clarify whether FHD-609-driven PROTACs act via proteasome-dependent turnover.

• Proteasome-Dependent Validation: FHD-609-containing PROTACs are well suited for confirming degradation mechanism through perturbation studies. Co-treatment with proteasome inhibitors or E1/E2 pathway modulators can demonstrate loss of degradation activity, while lysosomal inhibition controls help distinguish ubiquitin-proteasome processing from alternative clearance routes.

Structure: The structure of FHD-609 is characterized by primary or secondary amine/basic nitrogen centers. These features provide defined hydrogen-bonding, hydrophobic, and steric elements that can support affinity retention while enabling analogue-based linker-vector selection.

Reactivity: The amine/basic nitrogen-containing motif can be evaluated for acylation, sulfonylation, alkylation, or carbamate/urea linker installation when that vector is solvent exposed. For PROTAC construction, the POI ligand can be paired with CRBN ligands such as thalidomide, pomalidomide, or lenalidomide analogues, VHL ligands such as VH032 derivatives, or less common IAP/MDM2/cIAP-recruiting ligands, with alkyl, PEG, piperazine, triazole, or amide linkers screened for ternary-complex formation. In practice, incorporation into PROTACs should begin from derivatives that preserve the reported binding pharmacophore, followed by systematic variation of linker length, polarity, rigidity, and exit-vector geometry to optimize target engagement, E3 recruitment, and cellular degradation readouts.